Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy
ConditionStroke
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorChuansheng Zhao
About this trial
To evaluate the efficacy and safety of intra-arterial TNK bridging therapy following incomplete recanalization (2b ≤ eTICI \< 3) after mechanical thrombectomy for acute anterior circulation large vessel occlusion.
Eligibility criteria
Qualifiers
Age ≥ 18 years;
Time from symptom onset or last known well to randomization within 24 hours;
Clinical diagnosis of acute ischemic stroke caused by acute occlusion of the intracranial anterior circulation large vessels confirmed by CTA/MRA/DSA, including occlusion of the intracranial segment of the internal carotid artery, the M1 or M2 segments of the middle cerebral artery, with or without concomitant occlusion of the ipsilateral extracranial segment of the internal carotid artery;
NIHSS score ≥ 6, and meeting the current guidelines for mechanical thrombectomy;
Disqualifiers
Contraindications to intravenous thrombolysis (excluding time-based criteria);
DSA post-thrombectomy indicating dissection of the occluded artery, or intra-procedural flat-panel CT suggesting local hemorrhage or significant contrast extravasation;
Baseline NIHSS score not obtained;
Severe allergy or absolute contraindication to iodinated contrast media;
Trial design
Treatments tested in this trial
- Tenecteplase (0.0938mg/kg)
- Placebo
Treatment groups
344 Participants
are divided into 2 treatment groupsSponsors and collaborators
Chuansheng Zhao
Lead sponsor
First Hospital of China Medical University
Sponsor institution
Source ClinicalTrials.gov